Sparks commentary

Healthcare

Sparks

Isofol Medical (ST: ISOFOL) completes pre-IND meeting for arfolitixorin
Published by Arron Aatkar, PhD

Isofol Medical has announced the completion of a pre-IND meeting with the FDA for arfolitixorin. According to management, the meeting was a success, with the FDA providing positive feedback on the company’s clinical development plan for the candidate. This is an important milestone for Isofol, as it provides a foundation for further development efforts and potential eventual commercialisation in the US.

Isofol is currently evaluating arfolitixorin in a Phase Ib/II trial as a potential treatment for patients with metastatic colorectal cancer.

Latest

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue